PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS INFECTION IN CHILDREN: ACTIVE AND PASSIVE IMMUNIZATION

• Autor(a) principal: Lopes , Maria Clara Barroso Leite
• Data de Publicação: 2024
• Outros Autores: Silva , Ian isaias paes landim Ribeiro da, Cavalcante, Luciane Mari Brito, Pontes, Cleuma Regina Freitas de Almeida, Cardoso, Alexandre Bruno Veras Bogea, Lopata , Ana Lais Namie, Sousa , David Breno Silva, Bainha , Bruna cordeiro dos Santos, Landim, Maria Teresa de Oliveira Paes, Fontana, Isabela Meneses de Morais, Carvalho, Camila Mendes Costa, Campos , Natália Soella de Souza, Araújo , Shirlei de Oliveira Soares, Fernandes, Tenylle Botelho, Pimentel , Matheus Henrique Gomes
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Brazilian Journal of Implantology and Health Sciences
• Texto Completo: https://bjihs.emnuvens.com.br/bjihs/article/view/1738
• topic: Vírus Sincicial Respiratório, Bronquiolite, Doença.; Respiratory Syncytial Virus, Bronchiolitis, Disease

This article aims to carry out an analysis of the current medical literature on respiratory syncytial virus, discussing its prevention. Respiratory syncytial virus usually starts like a common cold, with symptoms such as runny nose, low-grade fever and cough. The disease can progress to shortness of breath, caused by bronchiolitis, an inflammatory condition of the bronchioles, which are smaller branches of the channels that transport air to the lungs — the bronchi. There are several vaccines under development for respiratory syncytial virus, using different technologies. In May 2023, the United States approved the world's first vaccine against the disease, suitable for the elderly.